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LETTERS TO THE EDITOR
Therapy of Fabry disease
To the Editor: Referring to a Nephrology Forum by
Siamopoulos et al [1] entitled “Fabry disease: Kidney in-
volvement and enzyme replacement therapy” in a recent
issue of Kidney International, we have to comment on
two issues:
(1) Dr. Siamopoulos claims, “The availability of en-
zyme replacement therapy remarkably improves out-
come of patients with Fabry disease.”
This contention has not been proven formally by ran-
domized controlled trials. The primary end points of two
clinical trials showed disappearance of microvascular en-
dothelial Gb3 deposits in renal biopsies [2] and decrease
of neuropathic pain [3] after several weeks of enzyme
replacement therapy. All other outcomes of the previ-
ously mentioned trials, such as decrease of resting global
cerebral blood flow [4], clearance of deposits in endomy-
ocardium and skin, quality of life, pain score [2], esti-
mated glomerular filtration rate, Gb3 plasma levels, and
cardiac conduction [3] have only been secondary end
points, and thus, remain hypothesis generating. Other un-
controlled studies suggested a decrease of left ventricu-
lar hypertrophy [5], a reduction in QRS duration [6], an
improvement in patients’ New York Heart Association
(NYHA) functional heart failure class [6], and an im-
provement of sweat function [7]. However, the design of
these trials precludes valid conclusion on the efficacy of
enzyme replacement therapy in Fabry disease.
(2) Dr. Siamopoulos also mentions “most heterozy-
gote women remain asymptomatic and have a normal
life span, only some expressing a few minor manifesta-
tions. Cardiac and renal manifestations in heterozygous
women are usually lacking.”
By way of contrast, two studies report that almost all
females show multisystem involvement [8] and a decrease
in life expectancy of about 15 years compared to the gen-
eral population [9].
Although enzyme replacement therapy [2, 3] may
hopefully reduce disease burden of female and male
patients with Fabry disease, the improvement of many
clinical end points still remains to be established. In the
meantime, the clinical observations obtained in patients
under enzyme replacement therapy should be considered
more critically.
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Reply from the Author
As far as evidence-based medicine is concerned, I agree
with Dr. Kleinert et al that the “outcomes” of patients
with Fabry disease after enzyme replacement therapy
(ERT) have not yet been confirmed in large randomized
controlled trials. However, in my opinion, the rarity of this
disorder should encourage us to take into consideration
results from several independent investigators referring
to a relatively small number of treated patients (as refer-
enced by Dr. Kleinert et al), or even case reports [1], and
the case of the first patient discussed in the Nephrology
Forum, which clearly prove the clinical benefit of ERT.
It is suggested that ERT should be initiated in all pa-
tients with Fabry disease [2], and treatment should ideally
begin as soon as clinical signs and symptoms are observed.
As I concluded in my discussion, I tried to raise aware-
ness of the nephrologists in diagnosing the disease early.
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Needless to say of course, that accumulation of collected
Fabry Registry data will contribute to evidence-based
care.
Regarding the comment on Fabry disease in women,
I agree that with time there is an increasing recognition
of clinical manifestations of the disease in female het-
erozygotes, and as I mentioned in the Forum discussion,
genetic and nongenetic factors can influence the sever-
ity and progression of the outcome. Although no females
have been included in the two large clinical trials (as ref-
erenced in the Forum and also cited by Dr. Kleinert et al),
it is also suggested that carriers with substantial disease
manifestations should be treated with ERT [2].
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The search for maturity. . .
To the Editor: Recently, my American colleagues pub-
lished results in the treatment of nonmaturing fistulas.
Their views differ from mine, and they referred to my
publications in a derogatory fashion [1]. I wrote that a
stenosis is diagnosed in all cases of delayed maturation
[2]. In 1997, Beathard diagnosed stenosis in 33% of cases
[3], and this rate has now skyrocketed to 78%. There is
no doubt that he will reach my rate of 100% in a future
article. He would first have to perform angiograms by ar-
terial puncture at the elbow to diagnose stenoses located
in proximal arteries.
I wrote that there is no opacification of collaterals with-
out stenosis of the main outflow vein. Figure 2 of Beat-
hard’s article is very informative because it shows an an-
giogram before occlusion of a tributary, but the authors
overlook the stenosis of the main vein, which explains
why this collateral was opacified (Fig. 1) [1].
Figure 1B [1] of the article shows that dilation of the
vein caused stenosis in the artery, which the authors over-
looked, and I am skeptical about the ability of this fis-
tula to deliver sufficient flow. This case should have been
treated by surgical creation of a new anastomosis, which
leads to higher patency rates [4].
Finally, the authors report amazingly high patency rates
and compare them to mine in a derogatory manner. I
treated truly immature fistulas with a mean age of 2.5
months compared with 4.5 in their article, and I salvaged
thrombosed fistulas, whereas they did not.
LUC TURMEL-RODRIGUES
Tours, France
Correspondence to Luc Turmel-Rodrigues, Department of Cardio-
vascular Radiology, Clinique St-Gatien, Tours, France.
E-mail: luc.turmel@wanadoo.fr
REFERENCES
1. BEATHARD G, ARNOLD P, JACKSON J, LITCHFIELD T: Aggressive treat-
ment of early fistula failure. Kidney Int 64:1487–1494, 2003
2. TURMEL-RODRIGUES L, PENGLOAN J, BAUDIN S, et al: Treatment of
stenosis and thrombosis in haemodialysis fistulas and grafts by inter-
ventional radiology. Nephrol Dial Transplant 15:2029–2036, 2000
3. BEATHARD G, SETTLE S, SHIELDS M: Salvage of the nonfunctioning
arteriovenous fistula. Am J Kidney Dis 5:910–916, 1999
4. OAKES D, SHERCK J, COBB L: Surgical salvage of failed radiocephalic
arteriovenous fistulae: Techniques and results in 29 patients. Kidney
Int 53:480–487, 1998
Differential diagnosis between
X-linked Alport syndrome and
thin basement membrane
nephropathy
To the Editor: We read with interest the edito-
rial by Gregory [1] to the article “COL4A3 mutations
and their clinical consequences in thin basement mem-
brane nephropathy (TBMN).” Correctly, the necessity is
stressed to clearly distinguish thin basement membrane
nephropathy (TBMN) from Alport syndrome (AS), es-
pecially when the family history of renal failure and deaf-
ness is lacking. We believe that some complementary in-
formation should be given.
When renal biopsy is not typical [only thin glomerular
basement membrane (GBM)], the immunohistochem-
istry evaluation for a(IV) chains in the GBM can eas-
ily distinguish TBMN from Alport syndrome because in
the latter a3/a4/a5 chains are abnormally distributed or
even absent [2, 3]. In addition, the use of skin biopsy has
been demonstrated to be a very useful tool for diagnosing
X-linked AS. The reliability of skin immunohistochem-
istry for diagnosis of X-linked AS has been estimated in
about 80% in affected males and is a smaller percentage
in female carriers [4].
Very recently, the use of confocal laser microscopy in
the examination of the epidermal basement membrane
(EBM) had been proven to be able to detect a5(IV)
